hc-030031 has been researched along with Cancer-Pain* in 2 studies
2 other study(ies) available for hc-030031 and Cancer-Pain
Article | Year |
---|---|
Role of TRPA1 expressed in bone tissue and the antinociceptive effect of the TRPA1 antagonist repeated administration in a breast cancer pain model.
Breast cancer-induced chronic pain is usually treated with opioids, but these compounds cause various adverse effects. Transient receptor potential ankyrin 1 (TRPA1) is involved in cancer pain; also, endogenous TRPA1 agonists are associated with cancer pain development. The aim of this study was to observe the antinociceptive effect of a repeated-dose TRPA1 antagonist administration and the production of endogenous TRPA1 agonists and TRPA1 expression in bone tissue in a model of breast cancer pain in mice. Second, we used a sequence reading archive (SRA) strategy to observe the presence of this channel in the mouse bone and in mouse bone cell lines.. We used BALB/c mice for experiments. The animals were subjected to the tumor cell inoculation (4 T1 strain). HC-030031 (a TRPA1 antagonist) treatment was done from day 11 to day 20 after tumor inoculation. TRPA1 expression and biochemical tests of oxidative stress were performed in the bone of mice (femur). SRA strategy was used to detect the TRPA1 presence.. Repeated treatment with the TRPA1 antagonist produced an antinociceptive effect. There was an increase in hydrogen peroxide levels, NADPH oxidase and superoxide dismutase activities, but the expression of TRPA1 in the bone tissue was not altered. SRA did not show TRPA1 residual transcription in the osteoblast and osteoclast cell lines, as well as for mice cranial tissue and in mouse osteoclast precursors.. The TRPA1 receptor is a potential target for the development of new painkillers for the treatment of bone cancer pain. Topics: Acetanilides; Animals; Bone and Bones; Cancer Pain; Female; Hyperalgesia; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Nociception; Purines; TRPA1 Cation Channel | 2021 |
Role of transient receptor potential ankyrin 1 (TRPA1) on nociception caused by a murine model of breast carcinoma.
Breast carcinoma causes severe pain, which decreases the quality of life of patients. Current treatments produce adverse effects and have limited efficacy. Transient potential receptor ankyrin 1 (TRPA1) is related to the onset of cancer and neuropathic pain. The aim of this study was to evaluate the involvement of TRPA1 in a model of breast carcinoma. We injected 4T1 cells in the fourth caudal mammary fat pad of female BALB/c mice, and after 20 days we observed mechanical and cold allodynia and spontaneous nociception behavior (mouse grimace scale detection, MGS). TRPA1 selective antagonist (HC-030031 or A-967079) administration or intrathecal administration of TRPA1 antisense (AS) oligonucleotide was performed. The activity of NADPH oxidase, superoxide dismutase (SOD) and hydrogen peroxide (H Topics: Acetanilides; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Cancer Pain; Cell Line, Tumor; Female; Hydrogen Peroxide; Hyperalgesia; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; NADPH Oxidases; Nociception; Oximes; Paclitaxel; Purines; Sciatic Nerve; Skin; Superoxide Dismutase; Thioctic Acid; TRPA1 Cation Channel | 2020 |